Jennifer Poon

2.1k total citations
16 papers, 278 citations indexed

About

Jennifer Poon is a scholar working on Pulmonary and Respiratory Medicine, Genetics and Oncology. According to data from OpenAlex, Jennifer Poon has authored 16 papers receiving a total of 278 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 8 papers in Genetics and 5 papers in Oncology. Recurrent topics in Jennifer Poon's work include Advanced Breast Cancer Therapies (8 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Acute Myeloid Leukemia Research (3 papers). Jennifer Poon is often cited by papers focused on Advanced Breast Cancer Therapies (8 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Acute Myeloid Leukemia Research (3 papers). Jennifer Poon collaborates with scholars based in United States, United Kingdom and Italy. Jennifer Poon's co-authors include Rajat Bannerji, Angela LaRosa, Karen Small, G. Shashidhar Pai, Yali Zhu, Da Zhang, Ying-Ming Jou, Paul Statkevich, Alison Walker and Maria R. Baer and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PEDIATRICS.

In The Last Decade

Jennifer Poon

15 papers receiving 270 citations

Peers

Countries citing papers authored by Jennifer Poon

Since Specialization

Citations

This map shows the geographic impact of Jennifer Poon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer Poon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer Poon more than expected).

Fields of papers citing papers by Jennifer Poon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer Poon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer Poon. The network helps show where Jennifer Poon may publish in the future.

Co-authorship network of co-authors of Jennifer Poon

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer Poon. A scholar is included among the top collaborators of Jennifer Poon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer Poon. Jennifer Poon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Efficacy and safety of azacitidine in pediatric patients with newly diagnosed advanced myelodysplastic syndromes before hematopoietic stem cell transplantation in the AZA‐JMML‐001 trial 2024 ·Pediatric Blood & Cancer ·Franco Locatelli, (unknown), Irene Schmid, Julián Sevilla, Owen Smith, Marry M. van den Heuvel‐Eibrink, Marco Zecca, C. Michel Zwaan, Allison Gaudy, Meera Patturajan, Jennifer Poon, Mathew Simcock, (unknown)	1
2	Phase 2 Study of Pomalidomide (CC-4047) Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors 2021 ·Frontiers in Oncology ·Jason Fangusaro, Maria Giuseppina Cefalo, Maria Luisa Garrè, Lynley V. Marshall, Maura Massimino, (unknown), (unknown), Jennifer Poon, (unknown), (unknown), (unknown), Mathew Simcock, (unknown), Darren Hargrave, François Doz, Katherine E. Warren	6
3	Results of a phase 2, multicenter, single‐arm, open‐label study of lenalidomide in pediatric patients with relapsed or refractory acute myeloid leukemia 2021 ·Pediatric Blood & Cancer ·Maureen M. O’Brien, Todd A. Alonzo, Todd M. Cooper, John E. Levine, Patrick A. Brown, (unknown), Keith J. August, (unknown), (unknown), Jennifer Poon, Meera Patturajan, Nianhang Chen, Mathew Simcock, (unknown), E. Anders Kolb	2
4	School-aged Children Who Are Not Progressing Academically: Considerations for Pediatricians 2019 ·PEDIATRICS ·Celiane Rey‐Casserly, Laura McGuinn, Arthur Lavin, (unknown), Rebecca Baum, (unknown), Thresia B. Gambon, (unknown), Lawrence S. Wissow, Carol C. Weitzman, Nathan J. Blum, David O. Childers, Jack M. Levine, (unknown), Jennifer Poon, (unknown), John I. Takayama, Robert G. Voigt, Carolyn Bridgemohan	9
5	A phase II clinical study of pomalidomide (CC-4047) monotherapy for children and young adults with recurrent or progressive primary brain tumors. 2019 ·Journal of Clinical Oncology ·Jason Fangusaro, Franco Locatelli, Maria Luisa Garrè, Lynley V. Marshall, Maura Massimino, (unknown), (unknown), Jennifer Poon, (unknown), (unknown), (unknown), Mathew Simcock, (unknown), Darren Hargrave, François Doz, Katherine E. Warren	4
6	Upfront azacitidine (AZA) in juvenile myelomonocytic leukemia (JMML): Interim analysis of the prospective AZA-JMML-001 study. 2019 ·Journal of Clinical Oncology ·Charlotte M. Niemeyer, Christian Flotho, Daniel B. Lipka, Jan Starý, Claudia Rössig, André Baruchel, Thomas Klingebiel, Concetta Micalizzi, Gérard Michel, Karsten Nysom, Susana Rives, (unknown), Marco Zecca, Irith Baumann, (unknown), Jennifer Poon, Mathew Simcock, Meera Patturajan, Marry M. van den Heuvel‐Eibrink, Franco Locatelli	6
7	Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies 2017 ·British Journal of Cancer ·Monica Mita, Alain C. Mita, Jennifer L. Moseley, Jennifer Poon, Karen Small, Ying-Ming Jou, Paul T. Kirschmeier, (unknown), Yali Zhu, Paul Statkevich, (unknown), John Sarantopoulos, James M. Cleary, Lucian R. Chirieac, Scott J. Rodig, Rajat Bannerji, Geoffrey I. Shapiro	48
8	Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias 2013 ·Cancer Chemotherapy and Pharmacology ·Ivana Gojo, Mariola Sadowska, Alison Walker, Eric J. Feldman, Swaminathan P. Iyer, Maria R. Baer, Edward A. Sausville, Rena G. Lapidus, Da Zhang, Yali Zhu, Ying-Ming Jou, Jennifer Poon, Karen Small, Rajat Bannerji	74
9	Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies 2012 ·Cancer Chemotherapy and Pharmacology ·Da Zhang, Monica Mita, Geoffrey I. Shapiro, Jennifer Poon, Karen Small, Anjela Tzontcheva, Bhavna Kantesaria, Yali Zhu, Rajat Bannerji, Paul Statkevich	23
10	Phase I study of the CDK inhibitor dinaciclib (SCH 727965) in patients (pts) with relapsed/refractory CLL. 2011 ·Journal of Clinical Oncology ·Joseph M. Flynn, Justin A. Jones, Leslie A. Andritsos, Kristie A. Blum, (unknown), (unknown), Elizabeth Wiley, NA Heerema, Jennifer Poon, Karen Small, Ying-Ming Jou, (unknown), Paul Statkevich, M. R. Grever, Rajat Bannerji, John C. Byrd	10
11	A phase I study of the CDK inhibitor dinaciclib (SCH 727965) administered every 3 weeks in patients (pts) with advanced malignancies: Final results. 2011 ·Journal of Clinical Oncology ·Monica Mita, Akira Mita, Jennifer L. Moseley, Jennifer Poon, Karen Small, Ying-Ming Jou, Paul T. Kirschmeier, (unknown), Paul Statkevich, Kamalesh K. Sankhala, John Sarantopoulos, (unknown), Lucian R. Chirieac, Scott J. Rodig, Rajat Bannerji, Geoffrey I. Shapiro	12
12	Right from the Start: Behavioral Intervention for Young Children with Autism, 2nd ed. 2011 ·Journal of Developmental & Behavioral Pediatrics ·Jennifer Poon	0
13	Developmental delay: Timely identification and assessment 2010 ·Indian Pediatrics ·Jennifer Poon, Angela LaRosa, G. Shashidhar Pai	46
14	Early Evidence of Anti-Lymphoma Activity of the Cyclin Dependent Kinase Inhibitor Dinaciclib (SCH 727965) In Heavily Pre-Treated Low Grade Lymphoma and Diffuse Large Cell Lymphoma Patients 2010 ·Blood ·Robert A. Baiocchi, Joseph M. Flynn, Jeffrey A. Jones, Kristie A. Blum, Craig C. Hofmeister, Jennifer Poon, Karen Small, Paul Statkevich, Michael R. Grever, Rajat Bannerji, John C. Byrd	9
15	Phase II Study of the Cyclin-Dependent Kinase (CDK) Inhibitor Dinaciclib (SCH 727965) In Patients with Advanced Acute Leukemias 2010 ·Blood ·Ivana Gojo, Alison Walker, (unknown), Eric J. Feldman, Swaminathan P. Iyer, Maria R. Baer, Jennifer Poon, Karen Small, Da Zhang, Mariola Sadowska, Rajat Bannerji	12
16	Update on the Phase I Study of the Cyclin Dependent Kinase Inhibitor Dinaciclib (SCH 727965) In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity and Feasibility of Long-Term Administration 2010 ·Blood ·Joseph M. Flynn, Jeffrey A. Jones, Leslie A. Andritsos, Kristie A. Blum, Amy J. Johnson, (unknown), Elizabeth Wiley, Jennifer Poon, Karen Small, Paul Statkevich, Michael R. Grever, Rajat Bannerji, John C. Byrd	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact